<DOC>
	<DOCNO>NCT02565576</DOCNO>
	<brief_summary>The purpose study evaluate safety , tolerability , pharmacokinetics/pharmacodynamics efficacy CFZ533 add-on therapy standard care patient moderate severe myasthenia gravis ( MG ) .</brief_summary>
	<brief_title>Safety , Tolerability , Pharmacokinetics Efficacy CFZ533 Moderate Severe Myasthenia Gravis</brief_title>
	<detailed_description />
	<mesh_term>Muscle Weakness</mesh_term>
	<mesh_term>Myasthenia Gravis</mesh_term>
	<criteria>1 . Diagnosis MG class IIa IVa inclusive ( Myasthenia Gravis Foundation America Clinical Classification ) . 2 . Quantitative Myasthenia Gravis ( QMG ) score 10 great . If QMG score &lt; 15 4 point may derive item 1 2 ( ocular motility disturbance ptosis ) . 3 . Documented history acetylcholine receptor ( AChR ) Muscle Specific Kinase ( MuSK ) antibody positive . 4 . Only one immunosuppressant immunomodulatory drug stable dose allow study ( ) azathioprine mycophenolate mofetil must stable least 4 month prior randomization ( ii ) cyclosporine must stable least 3 month prior randomization . 5 . If patient oral corticosteroid , methotrexate tacrolimus screening , dose must stable least 1 month prior randomization . 6 . If patient cholinesterase inhibitor screen , dose must stable least 2 week prior randomization . 7 . Women childbearing potential , defined woman physiologically capable become pregnant , may include study use highly effective method contraception study 12 week study treatment . 1 . MGFA grade I , IVb , V disease . 2 . Documented presence unresected thymoma . 3 . Patients undergone thymectomy thymo thymectomy ( resection thymoma ) within 6 month screen . 4 . Patients receive following treatment prior randomization : 1 . IVIg plasma exchange within 8 week ; 2. oral IV cyclosphosphamide treatment within 3 month ; 3 . IV corticosteroid bolus ( dose high 1 mg/kg ) within 3 month ; 4. belimumab within 6 month . For patient receive belimumab earlier , B cell count within normal range ; 5. rituximab within 12 month . For patient receive rituximab earlier , B cell count within normal range ; 6. biologic investigational drug within 1 month five time thehalflife , whichever longer . 7 . Live vaccine within 4 week study drug infusion . 5 . Patients significant risk TE judge investigator one following : 1 . History either thrombosis 3 spontaneous abortion without presence anticardiolipin autoantibody ; 2 . Presence prolong partial thromboplastin time ( PTT ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>CFZ533 , Myasthenia Gravis</keyword>
</DOC>